497 results on '"van der Veldt, Astrid A M"'
Search Results
2. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
3. Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
4. Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study
5. Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
6. Reproducible radiomics through automated machine learning validated on twelve clinical applications
7. Improved postprocessing of dynamic glucose-enhanced CEST MRI for imaging brain metastases at 3 T
8. Oncological healthcare providers’ perspectives on appropriate melanoma survivorship care: a qualitative focus group study
9. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis
10. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
11. A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
12. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
13. Comprehensive characterization of circulating tumor cells and cell‐free DNA in patients with metastatic melanoma
14. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
15. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab
16. Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.
17. The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer.
18. mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.
19. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
20. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
21. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
22. A prediction model for response to immune checkpoint inhibition in advanced melanoma
23. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
24. A prediction model for response to immune checkpoint inhibition in advanced melanoma
25. Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol
26. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
27. BRAF/MEK inhibitor rechallenge in advanced melanoma patients
28. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021
29. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
30. Detection of Drug-induced Interstitial Lung Disease Caused by Cancer Treatment Using Electronic Nose Exhaled Breath Analysis.
31. BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
32. A prediction model for response to immune checkpoint inhibition in advanced melanoma
33. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands
34. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
35. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.
36. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
37. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors
38. Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.
39. COVID-19 vaccination: the VOICE for patients with cancer
40. Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
41. Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
42. Supplementary Figure 2 from Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status
43. Supplementary Figure 1 from Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status
44. Adjuvant treatment of in‐transit melanoma: Narrowing the knowledge gap left by clinical trials
45. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
46. Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data
47. Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report
48. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis
49. Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma:a short report
50. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.